---
url: https://www.servicesaustralia.gov.au/solid-tumours-with-confirmed-ntrk-gene-fusion
title: Solid tumours with confirmed NTRK gene fusion - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:50.580Z
source: servicesaustralia.gov.au
---
# Solid tumours with confirmed NTRK gene fusion

The PBS subsidises larotrectinib for patients with solid tumours with confirmed neurotrophic tropomyosin receptor kinase (NTRK) gene fusion.

## on this page

-   [Patient eligibility](#a1)
-   [Authority applications](#a2)
-   [More information](#a3)

Please note: Youâ€™ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with larotrectinib under the _National Health Act 1953_, section 85 for patients with solid tumours with confirmed NTRK gene fusion.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](https://www.pbs.gov.au/pbs/home) on the PBS website outlines the restrictions for prescribing larotrectinib.

## Authority applications

### Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised larotrectinib to treat solid tumours with confirmed NTRK gene fusion can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [solid tumours with confirmed NTRK gene fusion - larotrectinib - initial authority application form](/pb333?context=20)
-   relevant attachments.

### Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised larotrectinib to treat solid tumours with confirmed NTRK gene fusion can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
